Every day you take around 20,000 breaths.
The struggle for breath is a struggle for life...
BreStem Therapeutics
Helping Patients Breathe Better
ABOUT US
BreStem is a clinical stage biotech company working to fight deadly lung diseases through stem cell and exosome therapies. The company’s lead candidate BRS101(autologous lung spheroid cells) has gained FDA approval as the world’s first IND using intrinsic lung-derived cells to treat pulmonary conditions. The company’s second candidate BRS201 (lung spheroid secretome/exosome) is currently at the preIND development stage.